PMID: 8477127Apr 1, 1993Paper

Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation

The Annals of Pharmacotherapy
W H AsburyC C Capers


To evaluate the frequency with which current loading and maintenance vancomycin dosages achieve target serum concentrations based on pharmacokinetic parameters obtained after the initial dose. Also, to identify the daily vancomycin dosage necessary to achieve target serum concentrations at steady-state and to determine if any relationships exist between vancomycin pharmacokinetic parameters and various patient characteristics. Neonatal intensive care unit (NICU) at Georgia Baptist Medical Center. Twenty-three infants with suspected or documented gram-positive infection who received intravenous vancomycin between July 1990 and November 1991 were included in this retrospective analysis. Gestational age range from 23 to 41 weeks and postconceptional age (PCA) at the time of the study ranged from 26 to 46 weeks. Vancomycin therapy was initiated with a loading dose of 15 mg/kg, followed by a maintenance dosage of 20-30 mg/kg/d, which was usually given as 10 mg/kg q8-12h. All vancomycin doses were administered using a syringe pump. Peak and trough serum concentrations were obtained following the first dose. Vancomycin pharmacokinetic parameters were determined using a one-compartment model. Infants receiving indomethacin within two w...Continue Reading


Oct 1, 1979·The Journal of Pediatrics·R F CifuentesS J Soldin
Apr 1, 1976·Journal of Pharmacokinetics and Biopharmaceutics·R J Sawchuk, D E Zaske
Jan 1, 1988·European Journal of Clinical Pharmacology·S M Lisby-Sutch, M C Nahata
Jan 1, 1987·Antimicrobial Agents and Chemotherapy·A JamesC Prober
Sep 1, 1987·Pediatric Research·M D ReedJ L Blumer
May 1, 1986·Pediatric Infectious Disease·D H SchaibleS A Plotkin
Jul 1, 1970·The Journal of Pediatrics·L M DubowitzC Goldberg
Oct 1, 1981·Archives of Disease in Childhood·O BattistiP A Davies
Jan 1, 1980·The Journal of Pediatrics·U B SchaadJ D Nelson

❮ Previous
Next ❯


Jan 7, 1999·The Journal of Pharmacy and Pharmacology·R SilvaA C Falcão
Jul 1, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alan D TiceUNKNOWN IDSA
Dec 16, 1998·Therapeutic Drug Monitoring·M YasuharaR Hori
Jun 1, 1997·Therapeutic Drug Monitoring·M V MilesP McGinnis
May 14, 2004·Clinical Pharmacokinetics·Matthijs de HoogJohn N van den Anker
Mar 30, 2004·Antimicrobial Agents and Chemotherapy·Toshimi KimuraKazuo Yago
Nov 3, 2010·British Journal of Clinical Pharmacology·María-Remedios Marqués-MiñanaJosé-Esteban Peris
Dec 14, 2011·Clinical Pharmacokinetics·Amélie MarsotNicolas Simon
Aug 4, 2011·Pediatrics International : Official Journal of the Japan Pediatric Society·Mitsuru IrikuraTetsumi Irie
Mar 13, 2014·Antimicrobial Agents and Chemotherapy·Julianne KimAndrew Simor
Nov 28, 2012·Clinical Pharmacokinetics·Amélie MarsotNicolas Simon
Sep 12, 2002·Clinical Pharmacokinetics·Jane Alcorn, Patrick J McNamara
Oct 18, 2000·Therapeutic Drug Monitoring·R E WrishkoD Hamilton
Jul 11, 1998·Pediatric Hematology and Oncology·N KrivoyM W Ben Arush
Feb 6, 2017·Journal of Clinical Pharmacology·Gilbert KochMarc Pfister
Apr 26, 2019·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Brady S MoffettPaul A Checchia
Oct 31, 2002·Clinical Pharmacokinetics·Jane Alcorn, Patrick J McNamara
Jan 15, 2014·Neonatal Network : NN·Robin B Knobel, Jennifer Marie Smith
Aug 21, 2015·Expert Review of Clinical Pharmacology·Evelyne Jacqz-AigrainMike Sharland
Sep 2, 1998·British Journal of Clinical Pharmacology·F PawlotskyJ C Roze

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.